iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
2.380
-0.230 (-8.81%)
Mar 9, 2026, 1:38 PM EDT - Market open
iBio, Inc. Employees
iBio, Inc. had 20 employees as of June 30, 2025. The number of employees increased by 4 or 25.00% compared to the previous year.
Employees
20
Change (1Y)
4
Growth (1Y)
25.00%
Revenue / Employee
$15,000
Profits / Employee
-$1,236,850
Market Cap
82.21M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Pliant Therapeutics | 171 |
| Seres Therapeutics | 103 |
| PolyPid | 73 |
| aTyr Pharma | 65 |
| PMV Pharmaceuticals | 47 |
| Pyxis Oncology | 44 |
| MAIA Biotechnology | 13 |
IBIO News
- 6 hours ago - iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - GlobeNewsWire
- 13 days ago - iBio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - iBio Announces $26 Million Private Placement - GlobeNewsWire
- 3 months ago - iBio to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 4 months ago - iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance - GlobeNewsWire
- 4 months ago - iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire